chronic
obstruct
pulmonari
diseas
copd
major
health
problem
worldwid
nearli
adult
unit
state
popul
copd
current
fourth
lead
caus
death
unit
state
copd
project
becom
third
lead
caus
death
worldwid
patient
establish
copd
infect
lower
respiratori
tract
frequent
present
exacerb
chronic
symptom
copd
acut
exacerb
copd
pneumonia
either
lead
complic
includ
respiratori
failur
requir
mechan
ventil
intens
care
unit
sever
mechan
account
increas
frequenc
sever
lower
airway
infect
copd
includ
anatom
abnorm
disord
mucu
secret
decreas
ciliari
clearanc
host
defens
defect
mucu
hypersecret
airway
cell
long
thought
consequ
shown
associ
worsen
lung
function
increas
frequenc
acut
exacerb
hospit
alveolar
macrophag
patient
copd
show
decreas
respons
nontyp
haemophilu
influenza
antigen
decreas
abil
phagocytos
bacteria
problem
caus
increas
suscept
damag
environment
insult
microbi
infect
caus
increas
baselin
lower
airway
inflamm
patient
copd
show
evid
increas
inflamm
airway
even
baselin
state
sputum
level
interleukin
il
neutrophil
elastas
myeloperoxidas
increas
patient
copd
compar
without
copd
chronic
symptom
cough
increas
sputum
product
dyspnea
present
baselin
episod
worsen
symptom
occur
period
exacerb
increas
airway
inflamm
observ
exacerb
creactiv
protein
level
blood
marker
system
inflamm
rise
exacerb
decreas
slowli
patient
improv
level
sputum
tumor
necrosi
factora
rise
exacerb
declin
convalesc
observ
suggest
symptom
acut
exacerb
caus
increas
airway
inflamm
clinic
diagnosi
acut
exacerb
copd
distinguish
pneumonia
absenc
lung
infiltr
chest
radiograph
former
longitudin
studi
explor
incid
acut
exacerb
patient
copd
gener
number
exacerb
per
year
increas
sever
copd
studi
patient
moder
copd
median
exacerb
rate
per
patient
per
year
exacerb
requir
hospit
associ
increas
mortal
persist
year
discharg
hospit
hallmark
copd
heterogen
clinic
cours
among
patient
sever
etiolog
account
acut
exacerb
copd
increas
airway
inflamm
rel
proport
caus
difficult
determin
part
difficulti
stem
inconsist
definit
acut
exacerb
variou
studi
concern
spectrum
acut
exacerb
defin
worsen
one
symptom
may
repres
differ
diseas
exampl
patient
purul
sputum
like
bacteri
infect
caus
acut
exacerb
mucoid
sputum
present
use
definit
one
propos
anthonisen
colleagu
studi
antibiot
acut
exacerb
copd
studi
antibiot
efficaci
exacerb
defin
increas
dyspnea
sputum
volum
purul
type
sever
two
symptom
type
moder
one
symptom
fever
symptom
upper
respiratori
tract
infect
type
mild
use
definit
variou
probabl
caus
worsen
lower
airway
inflamm
caus
acut
exacerb
box
anoth
reason
difficulti
precis
definit
proport
contribut
variou
etiolog
focu
one
etiolog
other
variou
studi
sever
studi
focus
role
bacteria
virus
acut
exacerb
studi
set
patient
one
group
hospit
patient
acut
exacerb
sputa
analyz
bacteria
cultur
virus
polymeras
chain
reaction
pcr
infecti
caus
establish
bacteri
viral
viralbacteri
coinfect
variou
author
estim
exacerb
caus
infect
bacteria
virus
environment
caus
exacerb
identifi
etiolog
see
box
mani
patient
copd
potenti
pathogen
bacteria
lower
airway
even
baselin
state
sever
studi
use
bronchoscopi
bronchoalveolar
lavag
bal
protect
specimen
brush
avoid
contamin
upper
airway
flora
recov
bacteria
patient
baselin
literatur
divid
role
bacteria
pathogenesi
copd
littl
doubt
bacteria
caus
least
acut
exacerb
copd
box
list
line
evid
show
bacteria
play
signific
role
caus
acut
exacerb
increas
pathogen
bacteria
exacerb
percentag
patient
pathogen
bacteria
lower
airway
increas
baselin
exacerb
pool
analysi
studi
use
protect
specimen
brush
sampl
show
pathogen
bacteria
present
lower
airway
stabl
copd
patient
patient
acut
exacerb
microbi
load
lower
airway
increas
rate
exacerb
rose
correl
increas
airway
inflamm
presenc
pathogen
bacteria
patient
exacerb
sputum
marker
inflamm
higher
bacteria
sputum
without
bacteria
furthermor
number
pathogen
colonyform
unit
increas
sputum
marker
inflamm
increas
observ
suggest
bacteria
contribut
increas
airway
inflamm
exacerb
copd
antibodi
respons
bacteria
patient
acut
exacerb
develop
antibodi
infect
strain
h
influenza
moraxella
catarrhali
show
trigger
humor
immun
system
bacteria
molecular
epidemiolog
part
confus
regard
role
bacteria
etiolog
agent
acut
exacerb
copd
isol
speci
bacteria
stabl
exacerb
state
factor
relat
differ
bacteri
pathogen
might
explain
paradox
older
studi
exacerb
pay
attent
differ
strain
bacteria
longitudin
studi
patient
copd
acquisit
new
strain
h
influenza
catarrhali
streptococcu
pneumonia
associ
significantli
increas
risk
exacerb
one
might
specul
older
strain
kept
check
neutral
antibodi
newer
strain
subject
limit
period
benefit
antibiot
acut
exacerb
two
recent
systemat
review
shown
antibiot
significantli
reduc
mortal
treatment
failur
sever
acut
exacerb
copd
exacerb
purul
sputum
antibiot
seem
less
benefici
mild
moder
exacerb
sputum
purul
absent
prior
studi
shown
presenc
purul
sputum
exacerb
report
patient
correl
higher
chanc
recov
pathogen
bacteria
sputum
studi
anthonisen
cowork
benefit
antibiot
therapi
acut
exacerb
mostli
type
group
three
symptom
increas
dyspnea
sputum
volum
purul
emphas
acut
exacerb
copd
syndrom
defin
symptom
subset
like
caus
bacteri
infect
caus
haemophilu
influenza
commonest
bacteri
pathogen
copd
fig
show
bacteri
isol
copd
studi
clinic
va
western
new
york
healthcar
system
buffalo
new
york
period
timothi
f
murphi
md
unpublish
data
respiratori
viral
infect
caus
acut
exacerb
hospit
copd
rhinoviru
influenza
viru
parainfluenza
viru
coronaviru
adenoviru
respiratori
syncyti
viru
human
metapneumoviru
associ
acut
exacerb
copd
gener
acut
exacerb
episod
probabl
caus
viral
respiratori
infect
pcr
techniqu
detect
virus
higher
proport
respiratori
secret
cultur
serolog
studi
patient
acut
exacerb
use
pcr
viral
cultur
nasal
secret
serolog
respiratori
virus
detect
evid
viral
infect
acut
exacerb
episod
rhinoviru
account
anoth
studi
group
author
report
detect
pcr
rhinoviru
induc
sputum
exacerb
episod
four
instanc
could
find
rhinoviru
nasal
secret
anoth
studi
patient
hospit
sever
exacerb
found
evid
viral
respiratori
infect
human
metapneumoviru
detect
use
pcr
respiratori
secret
patient
acut
exacerb
report
establish
associ
howev
causat
respiratori
virus
detect
patient
stabl
copd
detect
viru
pcr
need
mean
infect
case
studi
explor
causal
link
virus
acut
exacerb
need
virus
caus
acut
exacerb
yet
clearli
understood
rhinoviru
upper
airway
pathogen
also
capabl
replic
lower
airway
epithelium
respiratori
virus
especi
influenza
viru
caus
lower
airway
epitheli
cell
damag
addit
direct
cytotox
releas
cytokin
chemokin
lead
inflammatori
respons
releas
proteolyt
enzym
tissu
damag
secondari
bacteri
infect
follow
viral
respiratori
infect
worsen
inflamm
influenza
infect
increas
odd
infect
pneumonia
h
influenza
serolog
evid
chlamydophila
chlamydia
pneumonia
infect
without
isol
organ
report
patient
acut
exacerb
similarli
serolog
evid
acut
mycoplasma
infect
without
isol
microb
report
small
percentag
patient
acut
exacerb
ozon
particul
air
pollut
diamet
less
mm
shown
epidemiolog
studi
associ
acut
exacerb
linden
utah
number
hospit
admiss
exacerb
bronchiti
fell
local
steel
mill
close
go
back
prior
level
mill
open
number
atmospher
particl
less
mm
parallel
trend
atmospher
black
smoke
sulfur
dioxid
associ
increas
emerg
room
visit
acut
exacerb
copd
atmospher
pollut
tobacco
smoke
caus
loss
ciliat
cell
decreas
mucociliari
clearanc
mucos
gland
hypertrophi
increas
mucu
product
mucu
contain
glycoprotein
carbohydr
side
chain
bacteria
attach
noncompli
medic
incorrect
use
inhal
induc
exacerb
condit
like
heart
failur
pulmonari
embol
pneumothorax
mimic
symptom
acut
exacerb
consid
clinic
analysi
final
acut
exacerb
identifi
caus
copd
patient
pneumonia
present
symptom
similar
acut
exacerb
lung
infiltr
chest
radiograph
copd
rais
risk
communityacquir
pneumonia
patient
copd
communityacquir
pneumonia
higher
mortal
patient
without
copd
patient
nonpneumon
acut
exacerb
copd
among
patient
influenza
respiratori
ill
copd
risk
factor
develop
influenzaassoci
pneumonia
patient
pulmonari
infiltr
test
posit
influenza
respiratori
secret
often
superimpos
bacteri
pneumonia
caus
commonli
staphylococcu
aureu
pneumonia
mortal
high
around
patient
copd
often
treat
oral
glucocorticoid
acut
exacerb
often
inhal
corticosteroid
stuck
colleagu
metaanalysi
found
increas
rate
infect
patient
receiv
mg
prednison
per
day
receiv
mg
prednison
cumul
dose
invas
aspergillosi
well
describ
patient
prolong
neutropenia
receiv
highdos
steroid
usual
set
organ
transplant
hematolog
malign
sever
report
invas
aspergillosi
patient
without
problem
especi
copd
patient
longterm
steroid
therapi
diagnosi
often
made
death
mortal
high
possibl
aspergillu
pneumonia
consid
copd
patient
pulmonari
infiltr
respond
standard
therapi
acut
exacerb
copd
defin
patientreport
symptom
increas
baselin
mani
caus
acut
exacerb
copd
infect
involv
half
virus
caus
third
rest
bacteria
patient
pneumonia
similar
symptom
infiltr
chest
radiograph
patient
steroid
opportunist
infect
possibl
especi
patient
respond
standard
therapi
bronchiectasi
defin
perman
abnorm
dilat
bronchi
patient
often
chronic
baselin
respiratori
symptom
cough
increas
sputum
product
short
breath
symptom
intens
exacerb
lower
respiratori
tract
infect
bronchiti
pneumonia
complic
frequent
patient
bronchiectasi
compar
healthi
volunt
infect
play
promin
role
exacerb
probabl
baselin
symptom
exact
preval
bronchiectasi
unknown
new
zealand
survey
pediatrician
produc
estim
preval
children
noncf
bronchiectasi
report
unit
kingdom
found
preval
children
descript
diseas
similar
differ
countri
patient
decreas
surviv
compar
healthi
subject
keistinen
colleagu
follow
cohort
patient
bronchiectasi
finland
period
patient
bronchiectasi
higher
mortal
lower
qualiti
life
asthma
although
fare
better
copd
numer
factor
identifi
caus
bronchiectasi
includ
postinfecti
childhood
viral
respiratori
infect
bacteri
pneumonia
tuberculosi
inherit
diseas
ciliari
dyskinesia
autoimmun
disord
rheumatoid
arthriti
inflammatori
bowel
diseas
immun
defici
sizabl
number
patient
howev
idiopath
bronchiectasi
clearli
identifi
caus
adult
present
bronchiectasi
without
obviou
caus
genet
test
identifi
cf
patient
obviou
reason
chronic
infect
exacerb
patient
bronchiectasi
anatom
abnorm
bronchial
wall
damag
dilat
possibl
strictur
varicos
varieti
bronchiectasi
reduc
patient
abil
clear
respiratori
secret
segment
clearanc
bacteria
ciliari
mechan
also
affect
recurr
infect
lead
damag
bronchi
set
viciou
cycl
suppur
tissu
damag
recent
investig
focus
defect
host
defens
bacteria
patient
bronchiectasi
comparison
normal
person
immun
respons
nontyp
h
influenza
infect
yet
clear
repres
increas
suscept
inabl
clear
bacteria
certain
group
patient
prone
develop
bronchiectasi
respons
infect
secondari
effect
chronic
infect
baselin
symptom
suggest
chronic
inflamm
airway
worsen
exacerb
sputum
studi
show
increas
neutrophil
marker
inflamm
cytokin
includ
moreov
pathogen
bacteria
lower
airway
cultur
sputum
neutrophil
elastas
myeloperoxidas
tumor
necrosi
factora
system
marker
inflamm
includ
total
blood
white
count
neutrophil
count
erythrocyt
sediment
rate
creactiv
protein
increas
patient
bronchiectasi
baselin
compar
control
symptom
exacerb
respond
well
appropri
antibiot
report
support
role
bacteria
caus
exacerb
symptom
role
microb
baselin
state
symptom
less
clear
evid
support
role
come
studi
show
increas
bacteri
load
lower
airway
patient
studi
use
techniqu
avoid
contamin
upper
airway
flora
use
bronchoscopi
protect
specimen
brush
bal
patient
bronchiectasi
potenti
pathogen
bacteria
lower
airway
presenc
pathogen
bacteria
lower
airway
patient
often
term
colon
improv
baselin
symptom
longterm
antibiot
suggest
howev
bacteria
may
caus
inflamm
like
patient
chronic
lower
airway
inflamm
caus
least
part
pathogen
bacteria
patient
bronchiectasi
chronic
lower
airway
bacteri
infect
caus
exacerb
addit
noninfect
caus
eg
tobacco
smoke
microb
play
role
spectrum
pathogen
bacteria
isol
patient
baselin
exacerb
remark
similar
h
influenza
pseudomona
aeruginosa
pneumonia
catarrhali
common
bacteria
studi
h
influenza
commonest
pathogen
isol
nearli
patient
pneumonia
p
aeruginosa
next
frequent
lesser
proport
enterobacteriacea
nocardia
aureu
isol
recent
nontubercul
mycobacteria
ntmb
see
later
recogn
frequent
chang
baselin
microbi
situat
caus
exacerb
unclear
propos
go
beyond
certain
threshold
lower
airway
bacteri
load
caus
increas
inflamm
exacerb
recent
studi
copd
howev
point
acquisit
new
strain
caus
acquisit
clearanc
differ
strain
catarrhali
bronchiectasi
shown
dynam
process
intermitt
acquisit
clear
new
strain
copd
acquisit
new
strain
pathogen
bacteria
associ
significantli
increas
risk
exacerb
similar
mechan
possibl
bronchiectasi
remain
establish
isol
p
aeruginosa
correl
sever
clinic
diseas
bronchiectasi
occur
later
cours
diseas
could
caus
diseas
progress
like
effect
least
one
report
note
rate
declin
lung
function
wors
patient
infect
p
aeruginosa
suggest
bronchiectasi
becom
sever
increas
bronchial
wall
damag
p
aeruginosa
gain
foothold
serv
marker
sever
diseas
aureu
uncommon
isol
bronchiectasi
caus
cf
one
report
found
patient
bronchiectasi
persist
aureu
isol
sputum
high
incid
abnorm
sweat
chlorid
test
author
advis
persist
aureu
isol
bronchiectasi
prompt
test
cf
ntmb
recogn
caus
chronic
lung
diseas
includ
bronchiectasi
although
clear
mycobacterium
avium
complex
caus
nodular
infiltr
bronchiectasi
elderli
white
women
clear
ntmb
infect
occur
frequent
establish
bronchiectasi
fowler
colleagu
isol
ntmb
sputum
cultur
patient
bronchiectasi
howev
mani
patient
later
diagnos
cf
other
found
ntmb
uncommon
noncf
bronchiectasi
cf
common
lethal
inherit
disord
white
popul
inherit
autosomalrecess
disord
homozygot
clinic
diseas
heterozygot
carrier
gene
involv
code
cf
transmembran
conduct
regul
cftr
camp
regul
protein
function
chlorid
channel
apic
membran
epitheli
cell
epitheli
cell
airway
submucos
gland
airway
sweat
gland
nasal
epithelium
salivari
gland
biliari
tree
pancrea
va
deferen
intestin
express
gene
classic
triad
clinic
featur
increas
sweat
chlorid
pancreat
insuffici
chronic
pulmonari
diseas
caus
mutat
gene
code
cftr
median
surviv
age
gradual
increas
year
present
morbid
mortal
cf
caus
respiratori
ill
patient
cf
develop
pulmonari
infect
caus
limit
group
bacteria
earli
age
within
short
time
infect
becom
chronic
almost
imposs
erad
repeat
chronic
infect
lead
problem
growth
qualiti
life
ultim
respiratori
failur
death
except
mild
increas
acinar
diamet
submucos
gland
airway
lung
normal
appear
birth
patient
cf
gland
produc
mucu
increas
viscos
decreas
mucociliari
clearanc
particul
matter
bacteria
soon
birth
pulmonari
infect
start
intens
neutrophil
inflamm
airway
continu
life
mucopurul
exud
accumul
airway
caus
plug
smaller
airway
destruct
bronchial
wall
includ
cartilag
bronchiectasi
pneumonia
increas
respiratori
difficulti
occur
two
primari
issu
involv
pathophysiolog
lung
diseas
cf
increas
suscept
infect
lung
organ
excess
neutrophil
inflamm
cf
seen
organ
like
pancrea
intestin
combin
two
factor
lead
suppur
pulmonari
infect
increas
suscept
infect
probabl
caus
combin
host
pathogen
factor
lung
cf
present
unusu
fertil
environ
growth
bacteria
p
aeruginosa
seriou
pathogen
cf
flourish
cf
lung
rare
caus
infect
elsewher
mucociliari
clearanc
particul
matter
abnorm
cf
reduct
volum
periciliari
fluid
moreov
mucu
cf
viscid
greater
depth
caus
increas
oxygen
gradient
across
layer
increas
adher
bacteria
especi
p
aeruginosa
airway
epitheli
cell
occur
cf
cftr
propos
receptor
p
aeruginosa
caus
intern
bacteria
follow
apoptosi
cell
cf
defect
cftr
abl
function
similar
manner
abnorm
glycolipid
function
receptor
p
aeruginosa
pilin
increas
cf
airway
cell
mechan
factor
bronchiectasi
viscid
pool
mucu
pu
certainli
contribut
increas
suscept
airway
infect
cf
although
function
antimicrobi
peptid
shown
defect
cf
report
reduc
nitric
oxid
product
cf
airway
epitheli
cell
may
impair
kill
bacteria
unusu
host
environ
also
induc
phenotyp
chang
p
aeruginosa
favor
chronic
infect
although
infect
p
aeruginosa
strain
resembl
environment
strain
earli
year
diseas
chang
mucoid
strain
later
strain
produc
exopolysaccharid
algin
caus
coloni
look
mucoid
onset
chang
phenotyp
associ
worsen
lung
function
trigger
chang
clearli
known
seem
reason
assum
respons
host
environment
condit
variou
trigger
neutrophil
product
surfact
suboptim
dose
antibiot
propos
pseudomona
aeruginosa
also
chang
lipopolysaccharid
side
chain
structur
could
make
resist
antimicrobi
peptid
recent
evid
suggest
p
aeruginosa
produc
biofilm
biofilm
sessil
commun
bacteria
attach
surfac
live
extracellular
matrix
synthesi
indirect
evid
biofilm
format
cf
come
observ
discret
bacteri
coloni
cf
sputum
detect
quorumsens
signal
bacteri
commun
bacteria
biofilm
grow
slowli
resist
antibiot
addit
increas
suscept
patient
cf
abnorm
intens
prolong
inflammatori
respons
infect
cf
patient
increas
number
neutrophil
level
bal
fluid
compar
noncf
patient
irrespect
speci
pathogen
neutrophil
increas
bal
even
cultur
neg
infect
associ
increas
inflamm
marker
sputum
product
antiinflammatori
cytokin
reduc
bronchial
epitheli
cell
patient
cf
compar
normal
control
evid
point
disord
inflammatori
respons
infect
cf
airway
product
excess
inflamm
includ
neutrophil
elastas
dna
fragment
apoptot
neutrophil
contribut
anatom
damag
airway
plug
cours
cf
pulmonari
diseas
punctuat
recurr
exacerb
caus
increas
symptom
worsen
lung
function
trigger
episod
well
known
possibl
caus
viral
respiratori
infect
clonal
expans
p
aeruginosa
popul
dispers
within
airway
newborn
cf
respiratori
symptom
sign
within
first
year
howev
develop
cough
wheez
tachypnea
sever
symptom
vari
among
patient
symptom
worsen
common
childhood
viral
respiratori
infect
infant
mild
diseas
often
diagnos
older
child
becom
older
cough
becom
persist
child
abl
expector
increas
sputum
volum
purul
note
short
breath
lead
decreas
qualiti
life
defici
growth
may
appar
bronchiectasi
set
hemoptysi
mild
sever
occur
cough
wheez
purul
sputum
becom
daili
occurr
bronchial
cyst
develop
occasion
ruptur
caus
pneumothorax
exacerb
baselin
symptom
often
necessit
hospit
eventu
respiratori
failur
caus
death
patient
less
sever
phenotyp
cf
howev
patient
surviv
well
adulthood
adult
cf
lesser
frequenc
p
aeruginosa
infect
patient
cf
develop
pulmonari
infect
caus
limit
group
bacteria
list
bacteria
isol
cf
patient
grow
box
acquisit
variou
bacteria
vari
age
fig
p
aeruginosa
burkholderia
cepacia
probabl
aureu
associ
declin
clinic
statu
mortal
spectrum
bacteria
vari
age
aureu
report
first
organ
cultur
bal
within
first
month
life
cf
rosenfeld
colleagu
longitudin
studi
infant
cf
use
bronchoscopi
bal
report
h
influenza
commonest
infect
microb
age
year
h
influenza
declin
next
year
life
wherea
aureu
p
aeruginosa
increas
year
age
p
aeruginosa
bal
earli
adulthood
chronic
p
aeruginosa
infect
patient
cf
polymicrobi
chronic
airway
infect
analysi
patient
averag
pathogen
speci
per
sputum
cultur
staphylococcu
aureu
one
earliest
cultur
cf
patient
histor
aureu
thought
signific
treat
antibiot
definit
evid
howev
role
caus
infect
cf
lack
metaanalysi
antistaphylococc
antibiot
trial
show
although
sputum
clearanc
often
achiev
improv
lung
function
observ
report
author
howev
advis
treatment
aureu
sputum
percentag
methicillinresist
aureu
increas
across
unit
state
preval
cf
see
fig
similarli
evid
definit
role
nontyp
h
influenza
caus
lung
inflamm
cf
lack
often
earliest
bacteri
pathogen
cultur
howev
lower
airway
cf
patient
recent
work
shown
evid
h
influenza
form
biofilm
cf
airway
pseudomona
aeruginosa
import
pathogen
cf
onset
infect
p
aeruginosa
associ
declin
lung
function
mention
previous
rosenfeld
cowork
found
patient
p
aeruginosa
bal
age
year
serolog
studi
show
infect
probabl
occur
even
earlier
antibodi
p
aeruginosa
shown
blood
month
bacteria
recov
sputum
oropharyng
cultur
databas
cystic
fibrosi
foundat
show
young
adult
cf
chronic
p
aeruginosa
infect
see
fig
other
found
even
higher
incid
use
bal
cultur
p
aeruginosa
age
year
howev
combin
serolog
evid
p
aeruginosa
infect
femal
gender
homozyg
cftr
mutat
aureu
isol
sputum
identifi
risk
factor
earli
acquisit
p
aeruginosa
less
sever
phenotyp
cf
burden
p
aeruginosa
infect
less
common
seri
patient
adult
cf
mean
age
year
p
aeruginosa
airway
infect
present
initi
isol
p
aeruginosa
cf
phenotyp
resembl
environment
isol
seen
noncf
patient
earli
infect
clear
infect
differ
strain
clear
within
year
howev
p
aeruginosa
becom
persist
persist
extrem
difficult
erad
chronic
pseudomona
airway
infect
cf
defin
continu
presenc
p
aeruginosa
lower
airway
secret
greater
equal
month
presenc
two
precipit
antibodi
p
aeruginosa
chronic
infect
like
caus
strain
p
aeruginosa
mani
year
albeit
continu
genet
adapt
life
host
airway
well
establish
p
aeruginosa
chang
phenotyp
produc
algin
coloni
look
mucoid
p
aeruginosa
use
variou
strategi
surviv
longterm
basi
cf
patient
lung
evid
p
aeruginosa
produc
biofilm
biofilm
format
associ
product
rhamnolipid
facilit
dispers
bacteria
within
airway
biofilm
mode
growth
p
aeruginosa
downregul
virul
factor
tissu
invas
transcript
flagellin
protein
downregul
advantag
bacterium
flagellin
act
ligand
bacteri
recognit
protein
probabl
help
evas
detect
host
immun
system
effect
immun
respons
chang
mucoid
type
associ
declin
lung
function
well
establish
extrem
difficult
erad
p
aeruginosa
patient
mani
strain
resist
multipl
antibiot
infect
mucoid
p
aeruginosa
increas
mortal
morbid
cf
children
earli
cours
cf
howev
p
aeruginosa
infect
intermitt
offer
window
opportun
clear
infect
aggress
antibiot
therapi
denmark
strategi
markedli
reduc
proport
cf
patient
develop
chronic
infect
adolesc
earli
adulthood
initi
describ
pseudomona
cepacia
bacterium
renam
burkholderia
given
genu
later
work
show
prototyp
speci
b
cepacia
least
nine
genet
variant
genomovar
mani
name
new
speci
renam
b
cepacia
complex
clinic
diseas
caus
genomovar
sever
diseas
mostli
genomovar
b
cenocepacia
colon
infect
airway
cf
b
cepacia
sporad
report
incid
increas
dramat
frequent
coexist
p
aeruginosa
occur
later
diseas
b
cepacia
transmit
epidem
fashion
cf
patient
cf
clinic
outsideclin
social
interact
far
preval
b
cepacia
infect
remain
cf
popul
see
fig
canadian
cohort
cf
b
cepacia
colon
associ
increas
mortal
level
lung
function
burkholderia
cepacia
caus
three
type
host
respons
type
colon
airway
without
chang
clinic
statu
type
gradual
clinic
declin
frequent
exacerb
respiratori
symptom
declin
lung
function
type
abrupt
rapid
deterior
respiratori
failur
necrot
pneumonia
frequent
caus
death
type
respons
occur
girl
unfortun
b
cepacia
remain
resist
commonli
use
antibiot
stenotrophomona
maltophilia
alcaligen
xylosoxidan
previous
call
achromobact
xylosoxidan
gramneg
bacilli
recov
cf
airway
cultur
see
box
age
acquisit
later
p
aeruginosa
usual
late
adolesc
adjust
p
aeruginosa
infect
statu
neither
bacteria
affect
mortal
sever
cours
cf
pandoraea
apista
nonfer
gramneg
bacillu
report
infect
lower
airway
cf
burkholderia
pseudomallei
infect
melioidosi
report
cf
patient
northern
australia
larg
varieti
gramneg
bacilli
isol
sputa
patient
cf
includ
ralstonia
enterobacteriacea
burkholderia
gladioli
unclear
whether
bacteria
advers
affect
cours
diseas
cf
allerg
bronchopulmonari
aspergillosi
clinic
syndrom
wheez
pulmonari
infiltr
central
bronchiectasi
caus
sensit
aspergillu
mostli
aspergillu
fumigatu
oppos
invas
diseas
patient
immedi
cutan
hypersensit
fumigatu
increas
total
serum
ige
eosinophilia
serum
precipit
antibodi
fumigatu
incid
allerg
bronchopulmonari
aspergillosi
increas
cf
estim
vari
geograph
variat
differ
definit
diagnosi
two
larg
unit
state
databas
estim
preval
around
cf
wherea
larg
european
registri
report
patient
cf
atopi
higher
preval
preval
higher
late
adolesc
olivi
colleagu
report
preval
ntmb
patient
cf
avium
complex
account
caus
mycobacterium
abscessu
preval
higher
coastal
area
whether
isol
ntmb
repres
lung
diseas
matter
much
research
autopsi
studi
patient
cf
repeatedli
posit
antemortem
cultur
ntmb
like
granulomat
lung
diseas
autopsi
addit
repeatedli
posit
cultur
chang
highresolut
ct
show
bronchiectasi
lung
involv
also
suggest
need
treatment
patient
cf
often
treat
central
clinic
interpati
spread
virul
multidrugresist
pathogen
concern
interpati
transmiss
well
document
b
cepacia
p
aeruginosa
evid
interpati
spread
much
less
robust
maltophilia
xylosoxidan
cohort
patient
isol
infect
noninfect
shown
reduc
new
infect
b
cepacia
p
aeruginosa
metaanalysi
advis
separ
patient
b
cepacia
noninfect
patient
separ
patient
multidrugresist
p
aeruginosa
maltophilia
xylosoxidan
cf
patient
immunocompromis
patient
